Brian Clevinger

A Prolog co-founder and managing director, Brian has been involved in the commercialization of bioscience for more than 25 years. Prior to co-founding the firm, Brian was the CEO of vaccine developer Megan Health. He led the company from its founding in 1993 to its acquisition in 2000 by AVANT Immunotherapeutics. Prior to that, Brian was tapped by Alafi Capital to head its medical technology commercialization partnership with Washington University, A/W Company. Brian began his professional career at Washington University, where he held a tenured position, headed a research laboratory, and created a monoclonal antibody core facility. He holds a doctorate in immunology from Indiana University and was awarded an NIH-sponsored postdoctoral fellowship at Washington University.